EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.656
https://www.valueinhealthjournal.com/article/S1098-3015(23)03786-5/fulltext
Title :
EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03786-5&doi=10.1016/j.jval.2023.09.656
First page :
Section Title :
Open access? :
No
Section Order :
10138